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Abstract
Lo-MYC and Hi-MYC mice develop prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma as a result of MYC
overexpression in the mouse prostate[1]. However, prior studies have not determined precisely when, and in which cell
types, MYC is induced. Using immunohistochemistry (IHC) to localize MYC expression in Lo-MYC transgenic mice, we show
that morphological and molecular alterations characteristic of high grade PIN arise in luminal epithelial cells as soon as MYC
overexpression is detected. These changes include increased nuclear and nucleolar size and large scale chromatin
remodeling. Mouse PIN cells retained a columnar architecture and abundant cytoplasm and appeared as either a single layer
of neoplastic cells or as pseudo-stratified/multilayered structures with open glandular lumina—features highly analogous to
human high grade PIN. Also using IHC, we show that the onset of MYC overexpression and PIN development coincided
precisely with decreased expression of the homeodomain transcription factor and tumor suppressor, Nkx3.1. Virtually all
normal appearing prostate luminal cells expressed high levels of Nkx3.1, but all cells expressing MYC in PIN lesions showed
marked reductions in Nkx3.1, implicating MYC as a key factor that represses Nkx3.1 in PIN lesions. To determine the effects
of less pronounced overexpression of MYC we generated a new line of mice expressing MYC in the prostate under the
transcriptional control of the mouse Nkx3.1 control region. These ‘‘Super-Lo-MYC’’ mice also developed PIN, albeit a less
aggressive form. We also identified a histologically defined intermediate step in the progression of mouse PIN into invasive
adenocarcinoma. These lesions are characterized by a loss of cell polarity, multi-layering, and cribriform formation, and by a
‘‘paradoxical’’ increase in Nkx3.1 protein. Similar histopathological changes occurred in Hi-MYC mice, albeit with accelerated
kinetics. Our results using IHC provide novel insights that support the contention that MYC overexpression is sufficient to
transform prostate luminal epithelial cells into PIN cells in vivo. We also identified a novel histopathologically identifiable
intermediate step prior to invasion that should facilitate studies of molecular pathway alterations occurring during early
progression of prostatic adenocarcinomas.
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Introduction
Prostate cancer proceeds through a morphological progression
consisting of the development of prostatic intraepithelial neoplasia
(PIN), invasive adenocarcinoma, distant metastatic disease, and
androgen refractory metastatic disease [2,3,4,5]. The key mor-
phological features that are diagnostic of PIN and invasive
carcinoma cells are changes in nuclear morphology such as
enlargement of the nucleus, changes in chromatin structure, and
marked nucleolar enlargement [6,7,8,9]. A critical issue remaining
in cancer biology, including in prostate cancer, is determining the
phenotype and niche of the progenitor cell that becomes
transformed. Prostate epithelium consists of two distinct cell types,
basal and luminal. While there is still controversy in this field,
compelling evidence in both mice and humans suggests that
normal prostate epithelial tissue stem cells reside in the basal
compartment [10,11,12,13,14,15,16]. Since PIN cells have a
luminal cell-like phenotype and are topographically present within
the luminal compartment [7,17,18,19,20], we and others have
suggested that cells within the luminal compartment, perhaps with
features of both basal and luminal cells, are the targets for
neoplastic transformation [19,20,21,22]. Further, only luminal
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istic of human PIN and adenocarcinoma[20]. We have postulated
that atrophic epithelial cells, that often occur in large numbers in
regions of inflammation (e.g. proliferative inflammatory atrophy/
PIA), are often the target cells for transformation. This hypothesis
is based upon morphological transitions of atrophy to PIN, and at
times directly to micro-invasive adenocarcinoma, and rare
molecular alterations such as methylation of GSTP1 [23] and
telomere shortening [24]. Another possibility was recently revealed
by Wang et al., who showed that rare cells within the luminal
compartment of the mouse prostate, that express Nkx3.1 in an
androgen independent fashion (referred to as castrate resistant
Nkx3.1 expressing cells or CARNs), possess stem cell character-
istics and can be a target of neoplastic transformation[25]. But
how do these aberrantly proliferating atrophic cells, or other
luminal-like cells in non-atrophic epithelium, undergo transfor-
mation? The answer, at least in a significant fraction of cases, may
relate to MYC expression (Note that the official gene name for
what is commonly referred to as C-MYC is MYC).
MYC is an oncogenic transcription factor overexpressed in a
variety of tumor types [26]. In prostate cancer, since a region
encompassing the MYC locus (8q24) is amplified in late-stage/
aggressive tumors, it is widely held that MYC is involved in disease
progression [26,27,28,29]. Yet, a number of observations suggest
MYC may be involved in early phases of prostate cancer
development as well. For example, MYC mRNA is overexpressed
in the majority of all primary human clinical prostate cancer
lesions [30,31]. Further, marked overexpression of MYC protein
occurs in the nuclei of the majority of primary prostatic
adenocarcinomas, as well as, exclusively within the luminal
compartment of high-grade PIN lesions, the presumptive precur-
sor to many prostatic adenocarcinomas [31]. Together with the
findings that overexpression of MYC in the mouse prostate causes
PIN [1,32] that progresses to adenocarcinoma[1], and that MYC
can transform isolated human prostate epithelial cells into
tumorigenic cells when mixed with urogenital sinus mesenchyme
[33], these results suggest MYC overexpression may also be a
critical factor contributing to prostatic adenocarcinoma initiation.
The mechanisms by which MYC transforms cells have been
linked to its function as a nuclear transcription factor whereby it
regulates a large number of genes and pathways that control a
complex array of cellular processes including cell cycle progres-
sion, metabolism, ribosome biogenesis, protein synthesis, mito-
chondrial number and function, and stem cell self renewal
[34,35,36]. In addition, MYC overexpression can result in global
modifications to chromatin structure, which also may be critical
for its ability to transform cells [37,38,39]. Given that a large
number of potential changes induced by MYC may be required
for transformation, and that some genes and pathways are
regulated by MYC in a lineage/cell-type specific manner [36], it
is important to determine both the nature and timing of molecular
changes induced by MYC in specific target cell types in vivo. While
these studies can be performed in human tissues to a certain
extent, the inability to sample the human disease at multiple time
points during progression of PIN lesions precludes precise
determination of these events in humans. Genetically engineered
mouse models that ‘‘phenocopy’’ the human disease can help
decipher MYC’s role in transformation and progression in a given
lineage/cell type [36,40].
Hi-MYC and Lo-MYC mice are transgenic mouse models that
use either a portion of the rat probasin promoter (Lo-MYC mice),
or the modified ARR2/probasin promoter (Hi-MYC mice), to
overexpress human MYC in a prostate-specific manner [1]. These
mice develop PIN by 2 weeks (Hi-MYC) or 4 weeks (Lo-MYC) of
age and invasive adenocarcinoma of the prostate by 6 to 9 months
(Hi-MYC), or by 10–12 months (Lo-MYC). The phenotypes of the
Hi- and Lo-MYC mice share a number of similarities with the
human disease. For example, the histological features of PIN in
Lo-MYC and Hi-MYC mice recapitulate stereotypical findings in
human PIN and adenocarcinoma cells—atypical changes in
nuclear morphology including enlargement of the nucleus and of
nucleoli [1] (and see below). In addition, the phenotype of the
cancer lesions in these MYC-based models is exclusively
adenocarcinoma, with no evidence for the neuroendocrine
carcinoma phenotype observed in tumor models based upon T
antigen overexpression (e.g. TRAMP and LADY) [41,42,43,44].
Furthermore, microarray expression profiling studies defined a
gene expression signature of MYC-induced prostate cancer in Hi-
MYC mice that shares a number of features with human prostate
cancer [1,45]. While these findings have been important for our
understanding of the potential role of MYC in early human
prostate cancer formation, additional studies are needed to address
a number of enduring questions regarding MYC action in early
prostate neoplasia and its relevance to the human disease.
One of the remaining issues regarding the early stages of
neoplastic transformation is whether overexpression of MYC alone
is sufficient for transformation to occur. The outcome of
deregulated MYC expression is thought to depend on the overall
levels of expression. Low levels of MYC expression, which occurs
physiologically during cell proliferation in most cell types, is
generally tolerated by cells without engaging tumor suppressor
mechanisms, whereas high levels of MYC expression generally
induce apoptotic and other tumor surveillance pathways
[36,46,47,48]. This indicates that in some cell types MYC needs
to cooperate with other survival genes, which may or may not be
classical activated oncogenes or inactivated tumor suppressors, to
transform cells [36]. Further, ectopic MYC overexpression in some
contexts mayalso causecell cyclearrest[49] (e.g.human fibroblasts)
or even terminal differentiation[50] (e.g. human keratinocytes). In
other cell types, however, including prostate epithelial cells, MYC
appears capable of immortalizing these cells in vitro in a single step
without an apparent need for additional activated oncogenes or
inactivated tumor suppressor genes [33,51].
Another key question is whether changes in expression of a
number of genes known to be relevant to prostate cancer may be
explained, at least in part, by MYC overexpression. For example,
Nkx3.1 is a lineage-restricted phenotypic transcription factor
required for proper prostate development and secretory function
[52,53,54,55] which is often reduced in human prostate cancer
and PIN lesions [56,57,58]. The mechanism of loss of Nkx3.1 in
carcinoma is often related to loss of one allele of chromosome 8p
[58,59], and we have verified this finding in prostatic adenocar-
cinoma lesions [57]. In our recent study, however, most human
PIN lesions showed reduced NKX3.1 protein expression without
concomitant loss of chromosome 8p, as assessed by fluorescent in
situ hybridization (FISH) [57]. This finding in human PIN suggests
an additional mechanism, unrelated to chromosome 8p loss, for
Nkx3.1 reduction in some prostate neoplastic lesions. In the
present study we sought to determine in more detail by
immunohistochemistry the relation between the onset of MYC
accumulation and changes in Nkx3.1 protein and mRNA levels
and the dynamics of such changes during disease progression. Our
results suggest a new mechanism for Nkx3.1 loss in PIN and early
prostate cancer.
Invasion of epithelial cells through the basement membrane into
the stromal compartment is the pathognomonic event that
underlies the diagnosis of epithelial cancers (e.g. carcinomas).
The multistep process of invasive cancer formation reflects a
MYC Induces PIN in One Step
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transition states between the clearly preinvasive lesions, such as
PIN, and the fully invasive adenocarcinoma lesions. In this study,
we also examined the interface between PIN lesions and invasive
adenocarcinoma lesions in MYC driven mouse models and we
have identified a novel histopathologically definable intermediate
step in the progression of PIN to micro-invasive carcinoma. This
finding should prove useful for studies that delineate the molecular
and cellular and micro-environmental processes of epithelial cell
invasiveness.
Materials and Methods
Animal Husbandry
The experimental protocol was approved by the Animal Care
and Use Committee at Johns Hopkins University, and the animals
were cared for in accordance with institutional guidelines. The
transgenic mice used in this study (Lo-MYC and Hi-MYC mice)
were obtained from the Mouse Repository of the National Cancer
Institute Mouse Models of Human Cancer Consortium at NCI
Frederick, MD, USA. Lo and Hi-MYC mice are on the FVB
background. Mice were housed in an animal facility maintained
on a 12-h light/dark cycle, at a constant temperature (2262uC)
and relative humidity (55615%). Tap water and food were
available ad libitum. Hemizygous Lo-MYC mice on FVB
background were cross-bred with non-transgenic FVB breeders.
All control mice used at each time point were from FVB
littermates. Nkx3.1-MYC transgenic mice were generated by
pronuclear injection of single-cell FVB embryos essentially as
previously described [60].
Genotyping
Mouse-tail DNA was isolated using the DNeasy Blood & Tissue
Kit from QIAGEN (Valencia, CA) and subjected to a PCR-based
screening assay for genotyping. For Lo-MYC mice, primers were
selected for genotyping using the human MYC cDNA sequence as
follows: upstream primer, 59-CAAGACTCCAGCGCCTTCTC-
39 and downstream primer 59- AGCCTGCCTCTTTTCCA-
CAG-39, which resulted in a PCR product of 186 base pairs. For
genotyping Hi-MYC mice, the upstream primer (located within
the ARR2-PB promoter), 59AAACATGATGACTACCAAGC-
TTGGC-39 and the downstream primer (within the MYC cDNA
sequence) 59ATGATAGCATCTTGTTCTTAGTCTTTTTCT-
TAATAGGG-39 were used to generate a PCR product of 177
base pairs. Nkx3.1-MYC transgenic founders were identified by
Southern blot analysis of Bam HI digested genomic DNA using a
probe within exon 2 of Nkx3.1.
Histology
Mice were sacrificed by CO2 asphyxiation at various ages up to
24 months. The prostate lobes were dissected into ventral prostate
(VP), dorso-lateral prostate (DLP) and anterior prostate (AP), and
processed for histological and immunohistochemical analysis. In
addition, the seminal vesicle, ampullary gland, lung, liver, kidney,
spleen, colon and draining lymph nodes were immediately
dissected for histological analysis. All mice were also examined
carefully at necropsy for evidence of gross metastatic disease in all
major organs except the brain. The tissues were fixed in 10%
buffered formalin and examined by routine light microscopy after
hematoxylin and eosin (H&E) staining.
Antibodies
The anti-MYC antibody (rabbit monoclonal, clone Y69) was
from EPITOMICS (Burlingame, CA). The anti-Nkx 3.1 antibody
(rabbit polyclonal) was generated by the Bieberich lab [61]. Anti-
Androgen receptor (AR) antibody (rabbit polyclonal) was from
Santa Cruz Biotechnology (Santa Cruz, CA). The anti-Ki-67
antibody (rabbit polyclonal) was from Novocastra (Newcastle-
upon-Tyne, United Kingdom), and the anti-cleaved caspase 3
antibody (rabbit polyclonal) was from Cell Signaling Technology
(Danvers, MA). The anti-smooth muscle actin (SMA) antibody
(mouse monoclonal, clone 1A4) was from DAKO Cytomation
(Carpinteria, CA). The anti-b actin antibody (mouse monoclonal)
was from Sigma-Aldrich (St. Louis MO).
Immunohistochemistry
For antigen retrieval, slides were steamed for 40 minutes in
EDTA solution (Zymed, South San Francisco, CA) for MYC and
Nkx3.1. Slides were steamed for 40 minutes in DAKO Antigen
Retrieval Solution for AR, Ki67, cleaved caspase 3, and SMA.
Primary antibodies were incubated at the following dilutions:
1:300 for MYC, 1:200 for Nkx3.1, 1:250 for AR, 1:4800 for Ki67,
1:50 for cleaved caspase 3, and 1:1000 SMA. DAKO Catalyzed
Signal Amplification kit was used for MYC. DAKO EnVision+
detection system was used for Nkx3.1, AR, Ki67, cleaved caspase
3, and SMA. Staining was visualized using 3,39-Diaminobenzidine
(DAB) (Sigma, Saint Louis, MO, FAST 3,39-Diamino benzidine
Tablets) and slides were counterstained with hematoxylin.
Quantification of Immunostaining
Whole slides were scanned with the Aperio Scanscope CS at
2006 magnification and random fields were selected for
quantification using the open source software program, FrIDA,
as described [31].
Northern Blots
Total RNA (3 mg) was extracted from mouse ventral prostates
and separated on 1% glyoxal/DMSO/agarose gels (Ambion Inc.,
Austin, TX) and hybridized to either a human MYC or mouse
Nkx3.1 cDNA probe. The hybridization signals were normalized
with respect to the hybridization signal observed when the same
blots were probed with a b-actin cDNA probe.
Western Blots
Mouse ventral prostates were lysed in RIPA buffer. Equal
amounts of total protein were electrophoresed and transferred to
PVDF membranes for immunoblotting. Membranes were probed
with antibodies against MYC (Epitomics, 1:5000), Nkx3.1 (1:1000)
and b-actin (Sigma, 1:10,000) (as a control to demonstrate equal
protein loading). The membranes were incubated overnight at
4uC followed by 1 hour of incubation at room temperature with
the secondary horseradish peroxidase-conjugated Donkey poly-
clonal anti-rabbit antibody (1:5000 dilution, Amersham, Piscat-
away, NJ, USA for MYC and Nkx3.1) or anti-Mouse IgG, HRP-
Linked Whole Ab from sheep (1:5000 dilution, GE Healthcare
NA931) for actin. Proteins were visualized using an ECL
chemiluminescence detection system, following the manufacturer’s
protocol and Hyperfilm ECL (Amersham).
Generation of the Nkx3.1-MYC Transgene
To create the Nkx3.1-MYC transgene, a recombineering
targeting vector was generated consisting of the human MYC
open reading frame and a Kanamycin
r gene flanked by 59 and 39
Nkx3.1 homologous arms [61]. The targeting fragment was
removed from the vector and used to transform an E. coli SW102
strain [62] carrying the NK17/lacZ transgene [61] in the pClasper
shuttle vector [63]. Recombinants selected for Kanamycin
MYC Induces PIN in One Step
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restriction enzyme analysis. A clone with the expected band
pattern indicating that the MYC gene had correctly inserted into
the Nkx3.1 locus was sequenced to ensure that precise insertion
had occurred. In the final Nkx3.1-MYC transgene, transcription
initiates at the Nkx3.1 transcriptional start site and polyadenyla-
tion is signaled by the SV40 early poly(A) sequence. Translation
initiates at the Nkx3.1 start codon, proceeds through codons 2–6
of Nkx3.1 and three codons generated by cloning (GGG, glycine;
GAT, aspartate; CCA, proline), then continues from codon 2
through 438 of MYC. Translation is terminated by the MYC TAA
sequence.
Statistics
Comparisons between the extent of nuclear staining for Ki67
between tissue types were evaluated using the Kruskal-Wallis test
for equality of populations using Stata 8.0.
Results
Morphological Features of PIN Lesions in Lo-MYC Mice
Are Highly Similar to Human High Grade PIN
Since the ventral prostate was the most susceptible lobe in
terms of the development of prostatic neoplasia in our study of
Lo-MYC mice, it was chosen as the focus of most of our studies
presented herein. The morphology of mouse PIN lesions was
quite similar to that found in the human (Figures 1–2). The
characteristic changes of PIN include cytoplasmic hyperchroma-
sia, nuclear and nucleolar enlargement, and global changes in
chromatin pattern. These global chromatin changes predomi-
nantly consist of changes in distribution such that in normal
appearing cells the chromatin is nearly homogeneously distribut-
ed, but in PIN cells there are areas of chromatin clearing. This is
accentuated somewhat in mouse PIN, since in normal mouse
nuclei there are highly characteristic darkly staining punctate
areas of chromatin that are distributed throughout the more
homogeneously staining regions, and, these punctuate areas are
largely absent in the mouse PIN cells (Figures 1–2). Human high
grade PIN consists of a number of morphological variants. The
most common variant is referred to as ‘‘tufting’’, and an example
of this is shown in Figure 2. Like human high grade PIN, the Lo-
MYC PIN cells retained abundant amounts of cytoplasm and
maintained cellular polarity, such that they retained a columnar
appearance (like normal prostate luminal cell epithelium), with
basally located nuclei and apically located cytoplasm (Figures 1–
3). Also similar to most human high grade PIN lesions, the
glandular architecture of the PIN lesions in Lo-MYC mice
generally showed either a single cell layer, was pseudostratified, or
contained what appeared to be multiple layers; albeit even in
multilayered appearing PIN lesions the cells largely maintained
their polarity (see Figure 2 for direct comparison of mouse and
human high grade PIN). In addition, the glands in mouse PIN
maintained open lumens without cribriform formation or the
development of multi-layered solid glandular structures. There
was an increase in both mitotic figures (Figure 1) and cells with
the morphological appearance of apoptosis in mouse PIN glands
(most of which could be verified by IHC staining for cleaved
caspase 3, not shown). As a comparison, we examined a number
of mice from the Hi-MYC strain, and the histological features
were similar, although the rate of progression to pre-invasive (see
below) and invasive disease, as previously reported [1], was faster
in Hi-MYC. Also, in Hi-MYC the lobe distribution of lesions is
different and expanded [1] when compared to Lo-MYC. Since all
PIN lesions showed marked nucleolar enlargement, similar to
human high grade PIN, we propose to refer to these lesions as
high grade PIN and we submit that Lo-MYC and Hi-MYC mice
do not develop low grade PIN. As expected, the fraction of cells
staining for Ki67, a measure of cellular proliferation, was
markedly increased in the PIN lesions, as well as in other more
advanced lesions described below (Figure S1).
Figure 1. Morphological appearance of PIN lesions in the Lo-MYC mice in H&E stained tissue sections. This high power view shows the
marked nucleolar enlargement as well as global changes in chromatin architecture including large-scale chromatin clearing that occurs in the mouse
PIN cells as compared to the normal mouse prostate epithelial cells in an 8 week-old Lo-MYC mouse ventral prostate (original magnification 6006).
Note that the mouse normal epithelial cells (A) show a relatively homogeneous chromatin distribution that is interrupted by a number of darkly
staining punctate regions that are quite characteristic of mouse chromatin (arrows). This homogeneous chromatin distribution and the darkly
staining regions are virtually abolished in the PIN cells (B) as a direct consequence of the MYC overexpression. The normal appearing epithelium
contains only small nucleoli and much smaller nuclei than the PIN cells. Arrow in B indicates mitotic figure in PIN lesion.
doi:10.1371/journal.pone.0009427.g001
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Expression and Its Relationship to Nuclear Architectural
Alterations
We sought to determine precisely when MYC overexpression in
the Lo-MYC mice occurs and to correlate this with the onset of
morphological changes diagnostic of PIN. In the study by
Ellwood-Yen et al., the authors suggested that overexpression of
MYC was sufficient to cause early neoplastic transformation [1].
Western blot analysis at four weeks of age using the human-specific
9E10 antibody revealed increasing levels of MYC protein
expression in Lo- MYC and Hi-MYC mice [1]. However, a
precise correlation between the onset of MYC expression in situ
and morphological transformation was not reported upon [1],
most likely as a result of the poor performance of the 9E10
antibody (AM De Marzo, unpublished observations) and other
anti-MYC antibodies in immunohistochemical assays. Therefore,
until now it has not been clear whether MYC that was detectable
on western blot in PIN lesions in Lo-MYC and Hi-MYC mice
represented relatively low levels of expression in all prostate cells,
or whether a subset of cells expressed MYC at relatively high
levels. To circumvent this problem, we performed immunohisto-
chemistry using a newer commercially available rabbit monoclo-
nal antibody against MYC [31].
Using this antibody, detection of MYC protein was not seen in
all of the nuclei of the luminal epithelial cells, but rather was
heterogeneous and somewhat focal in expression, especially in the
very young mice (e.g. less than 8 weeks of age) (Figure 3).
Strikingly, MYC expression coincided precisely with the morpho-
logical changes characteristic of PIN (Figure 3). These findings of
coincident staining of MYC and morphological transformation
were identified in every mouse that we examined that showed PIN,
including other prostate lobes in Lo-MYC mice and a number of
Hi-MYC mice containing PIN lesions in various prostate lobes
(more than 50 mice with PIN have been analyzed to date). While
PIN lesions showed an increase in cells undergoing apoptosis (see
above) we did not find increased levels of apoptosis, or cell
proliferation, in regions of normal appearing prostatic epithelium
in the Lo-MYC or Hi-MYC mice. Thus, it does not appear that
induction of MYC overexpression in normal epithelial cells results
in the induction of apoptosis. These findings suggest that
accumulation of MYC protein is sufficient to transform prostate
luminal epithelial cells into PIN cells in vivo without a concomitant
need for additional alterations required to suppress apoptosis. Wild
type adult mice were often completely negative for MYC staining,
but some mice contained weak expression of MYC that was
predominantly found within the nuclei in the luminal compart-
ment and that we subsequently validated as authentic mouse Myc
by western blotting (data not shown).
PIN Develops Exclusively in Prostatic Luminal Cells in
Lo-MYC and Hi-MYC Mice
A recent study indicated that in mouse tumors that develop after
prostatic-specific deletion of Pten (driven by ARR2-Probasin-Cre),
the PIN cells appear to originate in the proximal regions of the
Figure 2. Morphological comparison of mouse and human normal appearing epithelium and PIN lesions. All images were taken at the
same magnification and processed similarly to allow direct comparisons (400 6). (A) Normal appearing mouse epithelium. (B) Normal appearing
human prostate epithelium. (C) PIN lesion in a Lo-MYC mouse prostate. (D) PIN lesion in a human prostate. Arrows indicate enlarged nucleoli.
doi:10.1371/journal.pone.0009427.g002
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Low power (original magnification 206) image of an entire lobe of a mouse ventral prostate at four weeks of age from a Lo-MYC mouse. Stains are
indicated above images. Sections are not directly adjacent but are within ,25–40 mM (of each other. Note the highly heterogeneous nature of the
staining for MYC and Nkx3.1. (D–F). Medium power (1006) view of regions shown in the box in Figure 3A. Regions corresponding to normal appearing
epithelium are circled in black, and regions corresponding to PIN lesions are circled in red. Note that regions of PIN are staining positively for MYC and
the same regions are staining at a much reduced level for Nkx3.1. Also note small area in panel E that lacks staining for MYC, indicated by the arrow,
which has strong positive staining for Nkx3.1 (indicated by the arrow in panel F). (G–I). Higher power image of region of transition between normal
epithelium and PIN (the lowermost gland in panels D–F). Here it is clearly evident that cells corresponding to PIN cells, as shown in the H&E section
(panel G) are the same cells that are staining strongly positive for MYC, and the same cells that have markedly reduced staining for Nkx3.1. (J) Western
blot (left) showing reduced Nkx3.1 protein in a Lo-MYC mouse ventral prostate with PIN, as compared to an FVB wild-type mouse at the same age (six
months). Northern blot (right) showing reduced Nkx3.1 mRNA in a Lo-MYC mouse ventral prostate with PIN as compared to an FVB mouse at the same
age (9 weeks). Top right shows MYC mRNA is highly elevated in another Lo-MYC mouse ventral prostate as compared to a matched FVB wild-type (9
weeks).
doi:10.1371/journal.pone.0009427.g003
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with characteristic mouse prostate stem cell markers (e.g. Keratin
8-, Keratin 5+, p63+, Sca 1+, CD49f+), or transiently proliferating
cells with a phenotype between basal and luminal cells (p63-,
Keratin5+, Keratin 8+)—luminal cells did not appear to be the
target of transformation [64]. In our studies of Lo-MYC and Hi-
MYC mice, morphological appearances indicate strongly that only
luminal cells, and not basal cells, are positive for high levels of
MYC staining and show morphological features of PIN. Further,
we found no proximal-distal predilection to the development of
PIN lesions. To more definitively determine whether basal cells
were potential targets of transformation in these mice, we stained
mouse prostates containing PIN from Lo-MYC mice with an anti-
Keratin 5 antibody. Figure 4 shows that cells that were positive
for Keratin 5 were localized exclusively within the basal
compartment along the basement membrane and did not show
features of enlargement or a morphological appearance of
transformation. In addition, we performed double-label immuno-
fluorescence in a number of Lo-MYC and Hi-MYC mice with
antibodies against p63 (another basal cell marker) and MYC, and
we found that in PIN lesions only cells devoid of p63 nuclear
staining were strongly positive for MYC (data not shown). These
results indicate that only luminal-like cells, without Keratin 5 or
p63, are targets of transformation in Lo-MYC and Hi-MYC mice.
Inverse Relationship between C-MYC and Nkx3.1 in PIN
Lesions
In the prior study by Ellwood-Yen et al., Hi-MYC mice showed
decreased Nkx3.1 mRNA and protein expression, with some
variable reduction in PIN lesions, and virtual complete reduction
in invasive adenocarcinoma lesions [1]. However, without MYC
IHC staining, the relation between the onset of MYC expression
and Nkx3.1 reduction could not be determined. Further, Ellwood-
Yen et al suggested that Nkx3.1 loss was a distinct event from the
onset of MYC expression such that its loss together with MYC
overexpression may be a critical cooperating event in mouse PIN
to adenocarcinoma transition [1]. In the present study using a
different anti-Nkx3.1 antibody raised against mouse Nkx3.1[61],
while very intense nuclear staining for Nkx3.1 was seen in virtually
all normal luminal cells in the mouse prostate (in all lobes), its
expression was dramatically decreased in PIN in all cases in Lo-
MYC and Hi-MYC mice examined (Figures 3). There appeared
to be a cell-by-cell correspondence between increased MYC and
decreased Nkx3.1 protein in PIN lesions. Decreased Nkx3.1
protein in Lo-MYC mice was also verified by western blotting of
ventral prostate lysates (Figure 3J). Thus, unlike the findings by
Ellwood-Yen et al., and more recently Song et al.,[65] that
identified marked reductions of Nkx3.1 only in invasive adeno-
carcinoma in MYC overexpressing mice [1], we identified such
reductions in PIN. In fact, as compared to mouse PIN lesions we
see increased Nkx3.1 in early pre-invasive and invasive lesions (see
below). That reduced levels of Nkx3.1 itself are not responsible for
the morphological changes diagnostic of high grade PIN is
evidenced by the findings that Nkx3.1
(2/2) knockout mice
[52,53,54], or mice with targeted disruption of Nkx3.1 alleles in
adulthood [66], show only very subtle changes such as hyperplasia
and mild dysplasia (PIN-like), and even these are clearly much less
pronounced that that seen in the Lo-MYC and Hi-MYC mice.
While the mechanism(s) by which MYC regulates Nkx3.1
protein in the mouse prostate is not clear, Ellwood-Yen et al.
showed that mouse Nkx3.1 mRNA was reduced by MYC [1],
suggesting that the regulation may at least in part be at the level of
mRNA. To determine whether reduced Nkx3.1 protein was
related to reduced Nkx3.1 mRNA levels in the ventral prostates of
Lo-MYC mice, we performed Northern blot experiments.
Figure 3J shows a clear reduction in Nkx3.1 mRNA in Lo-
MYC at 9 weeks of age, a time in which the majority of luminal
epithelial cells appear to be PIN cells (see below). Further, in
preliminary experiments in human prostate cancer cells that
express NKX3.1 (LNCaP cells), knockdown of MYC by siRNA
resulted in an increase in NKX3.1 mRNA and protein, showing
that MYC can indeed regulate NKX3.1 at the mRNA level (CM
Koh, AM De Marzo, manuscript in process).
Generation of Super-Lo-MYC Mice
A previously reported mouse strain in which mouse Myc was
driven by the rat C(3)1 promoter [32], which appears to be weaker
than the probasin promoter, found that low grade PIN lesions
developed with Myc overexpression, albeit these lesions did not
progress to invasive adenocarcinoma. Unfortunately this strain of
mice was lost by the time of the initial publication [32] so that we
cannot directly compare the levels of MYC in these mice to those
of the Lo-MYC mice.
Figure 4. Neoplastic appearing PIN and cribriform PIN/CIS cells and adenocarcinoma cells are negative for basal cell specific
Keratin 5 staining (original magnification 2006). (A) A mouse PIN lesion from a Lo-MYC mouse showing that neoplastic appearing cells are
negative for Keratin 5 and that there is a largely intact layer of benign appearing flattened basal cells. (B) A similar basal cell layer is highlighted by
staining positively for Keratin 5 in a cribriform PIN/CIS lesion. (C) A frankly invasive adenocarcinoma lesion in a Lo-MYC mouse, showing invasion into
the peri-prostatic fatty tissue, that is completely devoid of basal cells or any tumor cell Keratin 5 staining. Arrow indicates invasive adenocarcinoma
gland.
doi:10.1371/journal.pone.0009427.g004
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of MYC overexpression could cause transformation in mouse
prostatic epithelial cells in a new set of experiments. In order to
address whether forced overexpression of MYC at levels much
lower than those seen in Lo-MYC and Hi-MYC mice can also
result in PIN and/or adenocarcinoma, we generated a new
mouse strain that overexpresses human MYC in the prostate. For
this we used an Nkx3.1 cis-acting region, which has been
previously shown to result in prostate epithelial cell specific
expression of a reporter gene [61] to target human MYC
expression to the mouse prostate epithelium. Thirteen of 81
founder generation mice carried the transgene, and offspring
were successfully derived from 10. Analyses of transgene
expression by Northern blot and immunohistochemistry revealed
that only a single line expressed MYC in the prostate. Since MYC
may downregulate Nkx3.1 at the level of transcription (see above),
it is possible that elevated MYC itself may be responsible for
down-regulating Nkx3.1 expression. Thus, it appears that only
relatively low levels of MYC can be driven by this transgene. The
levels of MYC in these newly generated mice appeared
substantially lower than the levels seen in the Lo-MYC or Hi-
MYC mice when analyzed by IHC (Figure 5). Nevertheless, in
this mouse, which we designate ‘‘Super-Lo-MYC’’, we do see
changes consistent with foci of low grade PIN (Figure 5).
Importantly, while the degree of nuclear and nucleolar enlarge-
ment is less that that seen with Lo or Hi-MYC mice, these
changes in Super-Lo-MYC mice localize precisely to the cells that
overexpress MYC protein by IHC (Figure 5). These PIN lesions
also showed an increase in Ki67 staining fraction, and an increase
in apoptosis, albeit not nearly as pronounced in Lo-MYC or Hi-
MYC (not shown). These results appear similar to the previous
findings using the rat C(3)1 promoter [32], and suggest that even
moderate overexpression of MYC in the prostate results in cells
with the appearance of PIN (albeit low grade), and not in
apoptosis or cell cycle arrest.
Characterization of Cribriform PIN/Carcinoma In Situ as
Pre-Invasive Lesions
Most mouse models of human prostate cancer that have been
reported to date appear to progress through a phase in which the
morphological appearance of PIN lesions is distinctly different
than most human PIN lesions. In particular, unlike human PIN
lesions, the neoplastic lesions in these mouse models often fill or
nearly fill the lumens of the glands, as either solid sheets, as
cribriform structures, or as tufting or papillary structures [67,68].
Also, while some models show recognizable neoplastic lesions (e.g.
PIN) prior to the development of these more solid glandular
structures, the degree of nuclear atypia (which does not appear to
approach the degree we observe in models based on MYC
overexpression), generally does not increase significantly until the
neoplastic lesions have filled or nearly filled the lumens of the
glands.
Figure 5. Generation and characterization of the ‘‘Super Lo-MYC’’ mouse model. (A) Schematic representation of the recombineering
approach used to generate the Nkx3.1-MYC transgene. A MYC/KAN cassette flanked by Nkx3.1 homologous arms was recombined in bacteria with a
vector containing ,17 kb of the Nkx3.1 genomic locus. In the final transgene construct, the MYC-encoding mRNA initiates at the Nkx3.1
transcriptional start site and the SV40 early poly(A) signal (yellow box) mediates polyadenylation. (B–D) PIN lesion developing in a Super Lo-MYC
mouse. All magnifications are 1006. (B) H&E section in which PIN lesion is circled. (C) MYC IHC staining showing that a large fraction of cells in the PIN
lesion are staining weakly to moderately positive. (D) NKX3.1 is reduced in the same PIN appearing cells that are positive for MYC staining.
doi:10.1371/journal.pone.0009427.g005
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indicated above there is marked nuclear atypia at the earliest
recognizable stages, as in human PIN. Nevertheless, the PIN
lesions in these mice do evolve into cribriform lesions as an
apparent progression event (Figures 6 and 7). In addition to
multi-layering of cells, these changes in Lo-MYC were accompa-
nied by very distinctive cytological features which consist of a
variable decrease in cytoplasmic hyperchromasia, loss of polarity
and increased nuclear size and shape variability (e.g. pleomor-
phism) (Figures 6–7). The loss in polarity was characterized by a
loss in basally located nuclei within the PIN cells such that the cells
exhibited much more variation in the location of nuclei within
Figure 6. Characterization of cribriform PIN/CIS lesions in the Lo-MYC mouse model. (A) H&E section of an early cribriform PIN/CIS lesion,
without microinvasion, showing multilayering of cells partially filling the lumen. Note the loss of columnar cell polarity and the variable decreasei n
nucleolar size as compared to PIN lesions shown in Figures 1–3 (original magnification 2006). (B) Smooth muscle actin staining showing a highly
attenuated smooth muscle cell layer in the same lesion from an adjacent section (original magnification 2006). (C) H&E stained section of a more
advanced cribriform PIN/CIS lesion that shows early development of microinvasion, which is better shown in panel (D) by smooth muscle actin
staining (original magnification 1006). Black arrowheads showed regions of complete smooth muscle loss. Yellow arrowhead shows intact smooth
muscle layer around a PIN gland (C–D, original magnification 1006). (E) H&E section of another cribriform PIN/CIS lesion showing apoptosis and
necrosis towards the lumen (original magnification 2006). (F) Higher magnification view (6006) showing morphological evidence of apoptosis in a
different cribriform PIN/CIS lesion.
doi:10.1371/journal.pone.0009427.g006
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variation of nucleolar size and shape. Overall, there was a
reduction in nuclear and nucleolar size as compared with high
grade PIN lesions, although these atypical nuclear characteristics
were still much more prominent than seen in wild type mice
(Figures 6–7).
These morphological alterations in the cribriform PIN/CIS
lesions were also accompanied by molecular alterations. Interest-
ingly, MYC expression was somewhat decreased and staining for
Nkx3.1 was increased in many of these cells (Figure 7). Also, as
the cells piled up further, there was a marked increase in apoptosis
and frank necrosis towards the lumens (Figure 6E–F). Necrosis
has been identified in other genetically engineered mouse models
of human prostate cancer, and when it occurs, the authors refer to
the lesions as PIN IV [67].
That the cribriform PIN/CIS lesions are the precursors to
invasive adenocarcinoma was evidenced by the finding that in all
cases in which we identified microinvasive adenocarcinomas, there
appeared to be transitions into structures that were in the process
of microinvasion. As shown by reductions in smooth muscle actin
staining around the glands [67], the microinvasive lesions appear
to emanate from these morphologically transformed cribriform, or
partially cribriform lesions (Figure 6–7). The degree of nuclear
atypia decreased even further in the microinvasive lesions. We
interpret these findings as a kind of ‘‘paradoxical differentiation’’
occurring just prior to and at the point of invasion. Interestingly, in
most of the Cribriform-PIN/CIS lesions, there was a maintenance
of at least some basal cells, which were identified by staining for
Keratin 5 (Figure 4B) and p63 (not shown), despite the often near
complete loss of smooth muscle actin staining (Figures 6B and
6D). Only in a few of the more advanced lesions in Lo-MYC mice,
which in some cases showed invasion into the surrounding
prostatic fat tissue (Figure 4C), was there evidence for complete
loss of basal cells, indicative of unequivocal invasive adenocarci-
noma. Additionally, regions of early invasion showed a mild to
moderate lymphocytic inflammatory cell infiltrate around the
tumor cells (Figure 4C). IHC staining (CD3, CD4, CD8, CD20,
F4/80) indicated that most of these inflammatory cells are T cells,
with some B cells and a moderate number of macrophages as well
(not shown). Figure 8 shows our current progression model for
these lesions.
Since Androgen Receptor (AR) staining did not appreciably
change during the preinvasive and microinvasive processes
(Figure 7), it appears that alterations in AR levels cannot be
responsible for dynamic changes in MYC, Nkx3.1, or the
morphological changes. Although a number of Lo-MYC mice
were followed for up to 2 years of age (Table 1), most lesions in
mice that were 1 year or older showed numerous foci of cribriform
PIN/CIS, often with apparent microinvasion—no metastatic
lesions were identified. In the few examples in which the invasive
lesions appeared to grow larger in Lo-MYC mice, the MYC
expression increased and the Nkx3.1 staining was reduced, but
overall the Nkx3.1 staining was quite variable and much higher
than in the PIN lesions (not shown). The degree of nuclear atypia
(nucleolar enlargement and pleomorphism) increased in these
larger lesions as well (Figure 9).
In Hi-MYC mice, the lesions also progressed from high grade
PIN to cribriform PIN/CIS prior to the development of frank
invasive adenocarcinoma. Also, in Hi-MYC mice the reduction in
MYC protein seen in the cribriform PIN/CIS lesions and early
invasive lesions was present, but was not nearly so pronounced as
in the Lo-MYC mice (data not shown).
Frequency and Lobe Predilection of PIN and Early
Carcinoma Development
The overall frequency and lobe predilection for the develop-
ment of PIN and early invasive adenocarcinoma lesions in Lo-
MYC were similar to that reported by Ellwood-Yen et al. (Table 1)
[1]. All mice developed PIN in the ventral prostate by 4 weeks
(Figures 1–3). By 8 weeks of age most ventral prostates contained
PIN that occupied between 50 and 100% of the lobe. By one year
of age (52 weeks), all mice developed microinvasive adenocarci-
noma lesions, consisting of lesions apparently in transition to true
Figure 7. MYC levels are reduced and Nkx3.1 protein is markedly increased in cribriform PIN/CIS lesions. (A–D) Low power view
(original magnification 406) of the ventral prostate from a Lo-MYC MYC mouse at 1 year of age that contains residual PIN glands (*) and cribriform
PIN/CIS (circled in black dotted line). (E–H) A higher power view (original magnification 2006) of a different mouse showing both PIN and cribriform
PIN/CIS in the same microscopic field. Immunostains as indicated show a moderate reduction in MYC staining overall and a marked increase in Nkx3.1
in cribriform PIN/CIS areas. AR expression is retained in both PIN and cribriform PIN/CIS.
doi:10.1371/journal.pone.0009427.g007
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MYC mice. Relative levels of nuclear staining for Nkx3.1 and MYC are indicated. In normal epithelium, MYC levels are generally undetectable (2)
although low levels can be seen. Conversely, very high levels (++++) of Nkx3.1 are present in normal epithelium. In high grade pin lesions, MYC levels
are markedly elevated (++++), and Nkx3.1 levels are markedly reduced (+) as compared to normal epithelium. In cribriform PIN/in situ carcinoma
lesions, MYC levels are reduced somewhat compared to high grade PIN (+++), although still markedly above levels in normal epithelium. Here, Nkx3.1
levels are elevated (++) as compared to high grade PIN, although they are still somewhat reduced compared to normal epithelium. As invasive
tumors become somewhat larger, MYC levels increase again (+++), although they are not quite as elevated and are more variable than in the high
grade PIN lesions. Nkx3.1 levels (++) are also more variable here.
doi:10.1371/journal.pone.0009427.g008
Table 1. The phenotype of ventral prostate (VP) and lateral prostate (LP) in Lo-MYC mice and wild type mice.
Age VP in Lo-MYC LP in Lo-MYC Wild type
2W 4/4 benign 4/4 benign
4W 6/6 PIN 1/6 PIN
5/6 benign
4/4 benign
8W 1/8 PIN with cribriform PIN/CIS
7/8 PIN
5/8 PIN
3/8 benign
3/3 benign
12W 4/9 PIN with cribriform PIN/CIS
5/9 PIN
3/8 PIN with cribriform PIN/CIS
4/8 PIN
1/8 benign
4/4 benign
16W 3/3 PIN 2/3 PIN
1/3 benign
3/3 benign
5M 4/10 PIN with cribriform PIN/CIS
6/10 PIN
10/10 PIN 3/3 benign
7M 6/16 PIN with cribriform PIN/CIS
10/16 PIN
1/16 PIN with cribriform PIN/CIS
9/16 PIN
6/16 benign
7/7 benign
10M 2/3 PIN with cribriform PIN/CIS
1/3 PIN
2/3 PIN
1/3 benign
3/3 benign
12M 7/7 cribriform PIN/CIS with micro invasive adenocarcinoma 5/7 cribriform PIN/CIS with micro invasive adenocarcinoma
1/7 PIN
1/7 benign
4/4 benign
15M 4/4 cribriform PIN/CIS with micro invasive adenocarcinoma 1/3 invasive adenocarcinoma
1/3 PIN with cribriform PIN/CIS
1/3 benign
3/3 benign
18M 3/3 cribriform PIN/CIS with micro invasive adenocarcinoma 2/3 cribriform PIN/CIS with micro invasive adenocarcinoma
1/3 PIN
3/3 benign
21M 3/3 cribriform PIN/CIS with micro invasive adenocarcinoma 1/3 cribriform PIN/CIS with micro invasive adenocarcinoma
1/3 PIN
1/3 benign
3/3 benign
24M 10/10 cribriform PIN/CIS with micro invasive adenocarcinoma 7/10 cribriform PIN/CIS with micro invasive adenocarcinoma
2/10 PIN
1/10 benign
4/4 benign
In all cases, ‘‘invasive adenocarcinoma’’ indicates microinvasion into stroma as described in the text.
doi:10.1371/journal.pone.0009427.t001
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(Figure 4C). Between 4 weeks and 52 weeks, variable amounts of
PIN, and cribriform PIN/CIS with some apparent microinvasion
predominated. In the lateral prostate, 5 out of 8 cases showed PIN
at 8 weeks of age without invasion. By 52 weeks of age, 5 out of 7
mice developed microinvasive adenocarcinoma that also appeared
to be derived from cribriform PIN/CIS. In general, the area of
PIN, cribriform PIN/CIS, and microinvasive adenocarcinoma
lesions in the lateral prostate was markedly less than that in the
ventral prostate at the same age. The anterior prostate did not
show any neoplastic lesions, except that a single mouse developed
PIN at 18 months of age. The dorsal lobe did not show any
neoplastic lesions.
Discussion
We used the Lo-MYC mouse model to assess the onset and
dynamics of MYC protein accumulation within epithelial cells
during the development of PIN and the progression to localized
invasive prostatic adenocarcinoma. We show that the onset of
MYC protein overexpression coincides precisely with the mor-
phological transformation of mouse prostate luminal epithelial
cells into PIN cells—an appearance that is highly similar to human
high grade PIN. These changes include striking nucleolar size
expansion, large-scale chromatin redistribution, cytoplasmic
hyperchromasia, an increase in cell density, a marked increase
in proliferative fraction, and an increase in apoptosis. These results
support the hypothesis that overexpression of MYC, in the
absence of additional changes in other genes or pathways such as
those required to suppress MYC-induced apoptosis [1,33], is
sufficient to directly transform prostatic luminal epithelial cells into
PIN cells [1,32,33]. Since MYC overexpression occurs within
luminal epithelial cells in PIN lesions in human cells [31], the data
are also consistent with the hypothesis that epithelial cells within
the luminal compartment are the target cells for transformation in
the human prostate [19,20,22,25,31,69,70]. Whether any differ-
entiated epithelial cell within the luminal compartment can be the
target of MYC-induced transformation, or whether highly
specialized luminal cells such as CARNs[25] are the target, will
require further experimentation. In the current study, we also
found an inverse relation between the expression of MYC and the
phenotypic transcription factor/tumor suppressor, Nkx3.1 in PIN
lesions. Finally, our detailed examination of prostate morphology
in Lo-MYC (and Hi-MYC) mice uncovered an additional
intermediate step (cribriform PIN/CIS) in progression from
mouse PIN to invasive carcinoma. All of the morphological
features and changes that occur in Lo-MYC were also identified in
Hi-MYC, albeit with accelerated kinetics in Hi-MYC.
Dynamic Expression of MYC during Disease Progression
In Lo-MYC mice, the levels of MYC in the pre-invasive
cribriform PIN/CIS lesions and in early adenocarcinoma
lesions were decreased somewhat as compared to their
precursor high grade PIN lesions. Within the cribriform PIN/
CIS lesions, the largest reductions in staining were in cells
towards the lumens. These peri-luminal regions also showed an
increase in both apoptosis and necrosis. It is well recognized that
cells residing towards the lumens in multilayered cribriform
and/or solid intra-glandular neoplastic lesions have decreased
access to blood vessels and, therefore, decreased access to both
nutrients and oxygen. Since high levels of MYC result in high
nutrient demands on the rapidly proliferating neoplastic cells,
we postulate that these cells are either unable to survive (thus
undergoing apoptosis or necrosis), or, they have found a way to
reduce MYC levels, which in turn would reduce their level of
nutrient and oxygen use. Since AR levels did not appear to
change in these lesions, the reductions in MYC cannot be
explained by reductions in AR. Although Hif-1a, which is
stabilized and overexpressed in regions of hypoxia, has been
shown to repress MYC levels in other systems [71], we did not
find an increase in levels of Hif-1a staining either toward the
lumens of cribriform neoplastic glands, nor at the invasive front
of budding early adenocarcino m al e s i o n s( T .I w a t a ,A MD e
Marzo, unpublished results). When we examined hypoxia levels
more directly using pimonidazole labeling, we did find a small
increase in hypoxia-related staining in these inner regions near
the necrotic/apoptotic centers of the cribriform lesions, but we
did not see the same increase at the invasive fronts in the early
invasive lesions (T. Iwata, AM De Marzo, unpublished results).
T h u s ,i ti sl i k e l yt h a tr e d u c t i o n si nn u t r i e n ts u p p l i e s ,r a t h e rt h a n
hypoxia, may be a more important feature driving this
phenotypic switch. It is likely that the morphological appear-
ance of the PIN cells, which changed precisely at this time of
cribriform PIN/CIS development (the cytoplasmic hyperchro-
masia was reduced and cellular polarity was lost), also reflect an
underlying nutrient and/or hypoxic stress. The similar mor-
phological and phenotypic features of the cribriform PIN/CIS
cells, and the early invasive epithelial cells, suggest that the same
decrease in nutrient supply mayb ee x p e r i e n c e db yc e l l st h a t
have just invaded the stroma. This is also not unexpected since
it is likely that early invasive lesions would not possess an
elaborate and highly functional vascular network. The reduction
in nucleolar size, the decrease in cytoplasmic hyperchromasia,
t h ei n c r e a s ei nc y t o p l a s m ,a nd increase in Nkx3.1 in the
preinvasive and early invasive lesions suggest that these cells are
differentiating/maturing, albeit aberrantly. Similar characteris-
tics are well known to occur in some human preinvasive lesions
as they begin to invade the stroma (e.g. squamous cell
carcinoma in many body sites, and urothelial carcinoma) [72],
and, McNeal et al. proposed similar findings for human prostate
cancer early invasion [73]. The recovery of MYC protein and
Figure 9. Nuclear atypia resumes in larger adenocarcinoma
lesions. High power view (original magnification 4006) of an H&E
stained section of invasive adenocarcinoma lesion in Lo-MYC mouse
showing cells with large nucleoli, similar to that seen in PIN lesions.
These lesions stain nearly as strongly for MYC as PIN lesions, and there is
also fairly high levels of Nkx3.1 protein (e.g. much higher than PIN and
similar to cribriform PIN/CIS).
doi:10.1371/journal.pone.0009427.g009
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were observed upon enlargemento ft h ei n v a s i v et u m o r s ,a s
angiogenesis increases [1]. Although the extent was less, these
changes, which are suggestive of paradoxical differentiation, and
slowed growth, also occurred in Hi-MYC mice.
Dynamic Expression of Nkx3.1 during Disease
Progression
The prevailing model of NKX3.1 expression in human prostate
cancer suggests that while the protein may decrease in PIN lesions,
it is much more commonly decreased in invasive adenocarcino-
mas, and nearly completely lost in most, if not all, metastatic
prostate adenocarcinomas [52,59,74]. The aspects of this model
related to primary cancer lesions are generally supported by
Ellwood-Yen et al. who found in Hi-MYC mice that there was a
variable decrease in expression of Nkx3.1 in PIN lesions, and that
Nkx3.1 was virtually completely lost in invasive adenocarcinomas
[1]. In addition, Song et al. recently reported similar results [65].
However, several observations from our group regarding NKX3.1
differ from this prevailing view. First, in a previous report, while
reductions of NKX3.1 protein occurred in PIN lesions and some
adenocarcinomas, the reductions were relatively minor and
virtually all invasive adenocarcinomas retained significant levels
of NKX3.1 protein [57]. These results are similar to those
reported by Korkmaz et al. [75]. More recently we have found
that the majority of very high grade (Gleason score 8–10) localized
prostate cancers [76], and even almost all metastatic lesions from
hormone naı ¨ve patients (B Gurel, C Bieberich, AM De Marzo,
manuscript in revision), retain high levels of expression of NKX3.1
protein. In the present study we found that, as compared to high
grade PIN, the staining for Nkx3.1 protein actually increased
substantially in pre-invasive cribriform PIN/CIS lesions and in
early invasive adenocarcinomas, and these levels correlated
inversely with levels of MYC expression. These results indicate
the Nkx3.1 may be dynamically regulated during progression of
this disease. Interestingly, Nkx3.1 levels are high in budding
epithelial cells during prostate development [61,74], and mice with
targeted disruption of Nkx3.1 show reduced ductal branching
morphogenesis in all prostate lobes [74]. It is possible, therefore,
that Nkx3.1 expression in invasive prostatic acini in MYC-driven
mouse prostate cancers may represent a recapitulation or
caricature of the process of stromal invasion/branching morpho-
genesis in development, and, that Nkx3.1 may facilitate this
process.
Lei et al, found that in animals that were subjected to
conditional deletion of Pten in prostate epithelium, Nkx3.1 levels
were reduced [77], indicating that wildtype Pten levels are
required to maintain normal Nkx3.1 protein levels. Further, Lei
et al. found that forced restoration of Nkx3.1 expression in Pten
null epithelium led to decreased cell proliferation, increased cell
death, and prevention of tumor initiation [77]. They further
showed that Nkx3.1 was required to engage the p53 pathway,
indicating that reduced Nkx3.1 expression can itself abrogate p53
signaling. These findings raise the interesting possibility that the
reduction in Nkx3.1 seen upon the induction of MYC in the
mouse prostate prevents the induction of p53 induced apoptosis,
thus facilitating MYC’s ability to transform these cells. Additional
studies in which Nkx3.1 expression is kept at high levels during
induction of MYC in prostate epithelium will be required to
address this question further.
We do not know precisely how MYC is regulating Nkx 3.1
protein expression, although using gene expression array analysis
Ellwood-Yen et al. described a decrease in Nkx3.1 mRNA levels
in Hi-MYC mice[1]. Also, we found a decrease in Nkx3.1 mRNA
in Lo-MYC mice and an increase in Nkx3.1 mRNA levels in
human prostate cancer cells (LNCaP) after siRNA induced MYC
knockdown (C. Koh, AM De Marzo, unpublished observations).
Although further work is needed to determine whether this effect
is directly transcriptional, or post-transcriptional, these com-
bined results indicates that MYC regulates Nkx3.1 at the mRNA
level.
In the somewhat larger invasive tumors, many cells have both
high levels of MYC and high levels of Nkx3.1, which suggests
that the tight regulation of Nkx3.1 by MYC in the PIN lesions
appears to be lost to some degree in the invasive carcinoma
lesions. That the regulation of Nkx3.1 levels is complex is
evidenced by the fact that while Nkx3.1 levels are androgen
regulated in adult prostate epithelial cells, these levels are not
under androgen regulation during prostate development[59].
Also, Nkx3.1 is expressed in a number of other cell lineages
during development, including somites, and these lineages are
not under androgen regulation. In terms of transcriptional
regulation of mouse Nkx3.1, a 5-kb fragment downstream of the
Nkx3.1 coding region was shown to contain elements that
support expression in the prostate and bulbourethral glands,
whereas an upstream fragment was found to contain elements
that direct expression in somites and testes [61].
Compared to Lo-MYC mice, there was less of a reduction in
MYC in the cribriform PIN/CIS and early invasive lesions in Hi-
MYC mice. Yet, as in Lo-MYC, the levels of Nkx3.1 in these
lesions from Hi-MYC were much higher than in PIN lesions.
Taken together with the co-expression of high levels of MYC and
Nkx3.1 in the more advanced invasive carcinomas from Lo-MYC
mice, these results suggest that the large effects on downregula-
tion of Nkx3.1 by MYC only occurs in PIN lesions, with less of an
effect in pre-invasive and invasive lesions. This contention is also
supported by the fact that in human high grade PIN, while there
is reduction in the intensity of staining for NKX3.1 protein in
most cases, most of these same cases did not show loss of
chromosome 8p [57]. NKX3.1 protein levels, but not mRNA
levels, have also been shown to be markedly decreased in human
focal prostate atrophy (which is often associated with inflamma-
tion and designated as PIA) [57,78], lesions that do not show
clonal loss of chromosome 8p[57]. Consistent with this, the
inflammatory cytokines tumor necrosis factor (TNF)-alpha and
interleukin-1b have been shown to accelerate NKX3.1 protein
loss by inducing rapid ubiquitination and proteasomal degrada-
tion [79]. Further, Li et al, have shown that NKX3.1 protein
levels can be regulated by phosphorylation mediated by Protein
Kinase CK2, which itself is under complex regulation [80].
Taken together, it is clear that the regulation of NKX3.1 mRNA
and protein levels is highly complex, and additional studies will
be required to more fully determine in detail the molecular
mechanisms of control of NKX3.1 levels in different human and
mouse prostate lesions.
Are Other Genetic or Epigenetic Changes Needed to
Transform Prostate Epithelial Cells in Lo-MYC and Hi MYC
Mice?
The coincident occurrence of nuclear atypia and MYC
transgene expression strongly suggests that MYC accumulation
alone is sufficient to transform prostate epithelial cells into PIN
cells. It is likely that the reason that transgene expression does
not occur throughout the entire prostate epithelium, as might be
expected of the endogenous probasin promoter, is a result of the
well-known fact that the site of integration can affect the pattern
of expression in given transgenic lines[81]. In fact, quite variable
expression of transgenes driven by the minimal rat probasin
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reported upon previously [82]. Nevertheless, one cannot rule
out the possibility that there are other genes whose activity is
responsible for repressing MYC transgene transcription, the
accumulation of MYC mRNA, or the accumulation of MYC
protein, whose function must be altered in order for MYC
protein to ultimately accumulate in Lo-MYC and Hi-MYC
mice (or in Super-Lo-MYC mice). While the need for a
s e c o n d a r yc o l l a b o r a t i v ee v e n ts u c ha st h i si su n l i k e l yb e c a u s e
of the very rapid onset of the development of PIN in both Lo-
MYC and Hi-MYC mice, until an inducible system is developed
in which the transgene can be expressed at will in all target cells,
this question will remain somewhat open. Whether another
cooperating event is required in order to allow the accumulation
of MYC protein or not, it is still evident from our results that the
accumulation of MYC protein alone, once it occurs, is sufficient
to directly transform prostate epithelial luminal cells into PIN
cells.
Somewhat contrary to these results, Kim et al. recently
produced a different MYC-based mouse model in which MYC
was activated by removing a floxed ‘‘STOP’’ sequence (present
in the Z-MYC mice) using Cre recombinase driven by the
Probasin promoter (present in the Pb-Cre4 mice) [83]. In these
compound transgenic Pb-Cre4;Z-MYC mice, while some mice
overexpessing MYC showed evidence of PIN, there were a
number of mice that apparently overexpressed MYC in the
prostate epithelium that did not show PIN. Further, by crossing
these mice to mice with targeted disruption of Pten, it was shown
that the PIN lesions progressed much more rapidly into more
advanced PIN and early invasive adenocarcinoma lesions,
indicating cooperation between MYC and Pten [83]. While we
cannot yet determine why there is a discrepancy between these
findings by Kim et al. and our findings using Lo-MYC, Hi-
MYC, and Super-Lo-MYC, in terms of the issue of whether all
cells with MYC overexpression appear morphologically trans-
formed into PIN cells, it is possible that there are mouse strain
differences in the ability of MYC to directly transform prostate
luminal cells. The study by Kim et al. was carried out on a mixed
C57/B6 and 129 genetic background, whereas Lo-MYC, Hi-
MYC, Super-Lo-MYC, are all on the FVB genetic background.
Further studies that show acute overexpression of MYC in an
inducible fashion in different mouse strains may help resolve the
differences seen between these results.
Are Mouse Models of Prostate Cancer That Are Driven by
Transgenes under the Control of Androgen Receptor
Valid?
One potential criticism of AR-driven transgenic models of
prostate cancer is that the system does not reflect the human
disease. However, the discovery that a known oncogenic
transcription factor (e.g. ERG or ETV1-4) can be driven by AR,
as a result of the generation of fusion genes such as TMPRSS2-
ERG [84], should serve to alleviate such concerns. In fact, Sun et
al. have shown that ERG can drive expression of MYC [85].
While this is not proven in humans, it is quite intriguing and
further supports the relevance of MYC-based prostate cancer
models driven by AR as highly relevant to the human disease.
Certainly, additional studies to determine why MYC is highly
overexpressed in human PIN and adenocarcinoma lesions are
warranted. Given the fact that human high grade PIN and
adenocarcinoma lesions typically show a range of proliferative
fraction (as indicated for example by Ki67 staining) of between
approximately 3–40%, MYC levels in these lesions cannot be
elevated simply as a reflection of increased proliferation since in
most cases where MYC is overexpressed in human PIN and/or
adenocarcinoma, many more cells stain positive for MYC (often
60%–80% of cells stain positive) than could be accounted for by
simply increased proliferative fraction [31]. In addition, double-
label immunofluorescence in human prostatic adenocarcinoma for
MYC and Ki67 reveal a discordance in many of the cells (AM De
Marzo, Uzoma Anele, MengMeng Xu, unpublished observations).
A recent result may shed light on why MYC is overexpressed in at
least some prostate cancers. Wang et al. showed that targeted
disruption of FoxP3 (a gene that is critical to the development of
regulatory T cells) in the mouse prostate results in the
overexpression of Myc, prostatic hyperplasia, and PIN[86].
Further, they also showed that inactivating deletions or point
mutations are fairly common in the FOXP3 gene in human
prostate cancers and PIN lesions [86], and that FOXP3 can
directly repress MYC mRNA levels.
In summary, our new data shows that MYC appears to be
sufficient to morphologically transform prostate luminal epithe-
lial cells into PIN. Further, we verify that the histopathological
features of MYC driven mouse PIN and early adenocarcinoma
are highly similar to their human counterparts, and have shown
that Nkx3.1 mRNA and protein are negatively regulated in PIN
lesions by MYC. Additionally, we identified a time-dependent
intermediate step occurring prior to the development of invasive
adenocarcinoma in Lo-MYC and Hi-MYC mice. These findings
should facilitate studies into molecular alterations, including
profound biochemical changes, changes in global chromatin
architecture, and changes in the expression of multiple specific
genes that are induced by MYC that result in PIN and
subsequent invasive adenocarcinoma. Further, these studies
support the concept that MYC-based mouse models of prostate
cancer are useful ‘‘reagent mice’’ for studying the genetic,
epigenetic, and microenvironmental changes that cooperate
with MYC and lead to advanced and metastatic disease.
Supporting Information
Figure S1 Box plot showing increased proliferative fraction in all
neoplastic lesions in Lo-MYC mice. Standard slides were
immunostained against Ki67 as a marker of cell proliferation.
Slides were scanned at 2006 magnification using the Aperio
Scanscope CS and random snapshot fields were taken. Then, the
extent of brown staining (area fraction of Ki67) and blue staining
(area fraction of nuclei in question) were identified using FriDA
and a ratio of brown/(brown + blue) areas were determined. Each
dot in the box plots represents the average ratio from a number of
random images (minimum of 3 images per case). p values above
box plots indicate comparisons to normal mouse epithelium from
age matched FVB mice (Normal).
Found at: doi:10.1371/journal.pone.0009427.s001 (0.69 MB TIF)
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